Cambridge and Wetherby, UK: Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms announces that the next pre|CISION™ drug candidate, AVA3996, has been selected for pre-clinical development with a view to a first-in-human Phase I clinical trial...
Zyme Communications provides PR and marketing services for the life science sector. We support companies to raise their profile, build corporate value and generate interest from commercial leads, investors and partners.
Telephone: +44 (0)1223 968 920
Stirling House, Cambridge Innovation Park, Denny End Road, Waterbeach, Cambridge
Post Code: CB25 9QE
Country: United Kingdom
Membership Type: Corporate 6-20